Index

A
Access to HIV/AIDS Pharmaceuticals and Medical Technologies. See Executive Order 13155
Acquired immune deficiency syndrome. See Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS)
Active treatment concurrent control
equivalence (noninferiority) trial, 26
explanation of, iv, 26
Latin America proposed study use, ethical concerns, 25
placebo control vs., ethical concerns, 25
superiority trial, 26
See also Clinical trials; Control groups; Health care
Africa
Eastern/Southern, AIDS vaccine development efforts, 105
established effective treatment, example of, 10
health care services, 12
HIV perinatal transmission, placebo-controlled trials in, controversy, 1, 2
informed consent in biomedical research in, 36
informed consent involvement of community leaders, issues for, 43
post-trial benefits in international research, prior agreements on, criticisms of, 71
review of clinical trials, 83
sub-Saharan, HIV/AIDS drugs for, Executive Order on, 73
vaccine initiatives for, 73
Agency for International Development (USAID), 7, 80
equal protection provision for international research, in toto standard for, 87, 89
equal protection provision for international research, role of, 87–89
ethics review for protection of participants in international clinical trials, U.S. provisions for, 81, 82
host country capacity for international research, building, national/international guidelines reviewed by NBAC, 93
Agreement on Trade-Related Aspects of Intellectual Property Rights, 73
Agreements. See Agreement on Trade-Related Aspects of Intellectual Property Rights; Prior agreements
AIDS/HIV. See Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS)
AIDSVAX, 106
Alphavax Human Vaccines, Inc., 105
AMA. See American Medical Association (AMA)
American Home Products, 73
American Medical Association (AMA), 24
Argentina
informed consent documentation requirements, issues, 49
Asia
health care services, 12
HIV perinatal transmission, placebo-controlled trials in, controversy, 1
Assurances of compliance
independent evaluation of procedures for protection of participants in international clinical trials, NBAC recommendations, xi, 80
protection of participants in international clinical trials, U.S. procedures for, xi, 14, 78–80
protection of participants in international clinical trials, U.S. procedures for, OHRP proposed revisions to, 80
See also Cooperative Project Assurance (CPA); Federalwide Assurance (FWA); International Cooperative Project Assurance; Multiple Project Assurances (MPAs); Single Project Assurances (SPAs)
Australia
ethics review for international clinical trials, 82
National Statement on Ethical Conduct in Research Involving Humans, 93
protection of participants in international research, xiii, 14, 100
Aventis Pharma, 73
AZT, 2
B
Barriers. See Cultural barriers
Benefits
AIDS vaccines development, prior agreements on post-trial benefits, 66, 106–108
disclosure requirements for participants informed consent, in international clinical trials, v–vi, 37
equitable distribution for U.S. government-sponsored international clinical trials, NBAC recommendations, iii, 6
post-trial, and researcher-participant relationship in international research, ethical issues, 58–59
post-trial, disclosure requirements for informed consent in international research, NBAC recommendations, vi, 40
post-trial, ethical issues for in international research, viii–x, 12–13, 55–74
post-trial, for host country from international research, NBAC recommendations, x, 74
post-trial, for host country from international research, prior agreements on, NBAC recommendations, x, 74
post-trial, for others from international research, ethical issues, x, 12–13
post-trial, for participants in international research, justice as reciprocity and, 59–61
post-trial, for participants in international research, NBAC recommendations, x, 74
post-trial, IAVI prior agreements for international research, description, 66, 74, 104–106
post-trial, obligations of public/private research sponsors in international research, 64–65
post-trial, obligations of researchers in international research, 64
post-trial, obligations to host community/country in international research, ethical concerns, 61–64
post-trial, obligations to participants in international research, 56–58
post-trial, prior agreements for international research, and breach of obligations potential, 72, 74
post-trial, prior agreements for international research, and creation of double standard, issues, 71–72
post-trial, prior agreements for international research, and delay/prevention of research, 68
post-trial, prior agreements for international research, and funding/distribution problems, 67–69
post-trial, prior agreements for international research, and health policy influence, issues, 70–71
post-trial, prior agreements for international research, and prevailing international standard, issues, 70
post-trial, UNAIDS prior agreements for international research, 66, 74, 108
post-trial, VaxGen prior agreements for international research, 66, 74, 106–108
post-trial, WHO prior agreements for international research, 66, 74, 103–104
Thailand AIDS vaccine research, VaxGen prior agreements on post-trial benefits, description, 66, 108–108
Benin
post-trial benefits in, UNAIDS prior agreement for, 108
Berkeley, Seth, 105, 106
Bill and Melinda Gates Foundation
research initiatives of, timeline 2000–2001, 73
Bioethics Commission. See National Bioethics Advisory Commission (NBAC)
“Body Hunters,” 107
Boehringer Ingelheim, 73
Botswana
HIV/AIDS prevention in, funding for, 73
Brazil
National Health Council (NHC), 57
post-trial benefits in, UNAIDS prior agreement for, 108
post-trial obligations to international research participants, provisions for, 57, 62, 70
protection of international research participants, documents concerning, comparative analysis of, 100
Resolution No 196/96 on Research Involving Human Subjects, 90, 93
Bristol-Myers Squibb, 73

C
California, 66, 106
Canada
AIDS vaccine development funding for IAVI, 106
established effective treatment, example of, 10
ethics review for international clinical trials, 82
international research activities of, 3
post-trial obligations to international research participants, provisions concerning, 57, 70
protection of international research participants, xiii, 14, 100
Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, 57, 87, 93
Capacity
building, for design/review/conduct of international research by developing countries, strategies for, NBAC recommendations, xiv, 91
building, for ethics review of international clinical trials by developing countries, assistance for, NBAC recommendations, xiv, 94
building, for review/conduct of international clinical trials by host country, necessity of, xiii–xiv, 14, 89–94
Caribbean
HIV perinatal transmission, placebo-controlled trials in, controversy, 1
CDC. See Centers for Disease Control and Prevention (CDC)
Centers for Disease Control and Prevention (CDC), 7, 50, 79, 107
informed consent process for international clinical trials, NBAC recommendations, viii, 50
CEUs. See Clinical Epidemiology Units (CEUs)
Chapel Hill, North Carolina, 73
See also North Carolina
Children's Hospital
Children's Research Institute, 105
Chile
informed consent documentation requirements, issues, 49–50
China
AIDS vaccine development efforts, 106
Committee on Research Involving Human Subjects, 93
Guidelines on Ethical Review of Medical Research, 93
protection of international research participants, documents concerning, comparative analysis of, 100
CIOMS. See Council for International Organizations of Medical Sciences (CIOMS)
Clinical Epidemiology Units (CEUs), 91
Clinical trials
Add-on design for, description of, 22
AIDS vaccines development, prior agreements on post-trial benefits, 66
alternative therapies disclosure requirements, cultural barriers to, 39–40
assurances of compliance, for protection of international research participants, xi, 14, 78–80
informed consent role of others for international research, NBAC recommendations, vi, 43
multiple ethics review for international research, issues, 82–85
parallel group design, description of, 22
participant population selection for, 29
participants fair/respectful treatment in international research, v–vii, 10–12
participants in international research, ethical requirements for, 5–6
participants standard of care in international research, 9, 26–28
phases of, summary of, 21
pivotal (confirmatory) trials, description of, 21
post-trial benefits for host country in international research, NBAC recommendations, x, 74
post-trial benefits for host country, prior agreements for international research, NBAC recommendations, x, 74
post-trial benefits for others in international research, ethical issues, x, 12–13
post-trial benefits for participants in international research, NBAC recommendations, x, 74
post-trial benefits, and researcher-participant relationship, ethical issues, 58–59
post-trial benefits, disclosure in informed consent documents for, NBAC recommendations, vi, 40
post-trial benefits, IAVI prior agreements for international research, 66, 74, 104–106
post-trial benefits, in international research, ethical issues, vii–x, 12–13, 55–74
post-trial benefits, obligations of public/private research sponsors, 64–65
post-trial benefits, obligations of researchers, 64
post-trial benefits, obligations to host country of international research, ethical concerns, 61–64
post-trial benefits, obligations to participants in international research, concerns, 56–58
post-trial benefits, prior agreements on international research, discussion, 66–72, 74, 103–108
post-trial benefits, prior agreements on, and breach of obligations potential, 72, 74
post-trial benefits, prior agreements on, and creation of double standard, issues, 71–72
post-trial benefits, prior agreements on, and delay/prevention of research, 68
post-trial benefits, prior agreements on, and funding/distribution problems, 67–69
post-trial benefits, prior agreements on, and health policy influence, issues, 70–71
post-trial benefits, prior agreements on, and prevailing international standard, issues, 70
post-trial benefits, UNAIDS prior agreements for international research, 66, 74, 108
post-trial benefits, VaxGen prior agreements for international research, 66, 74, 106–108
post-trial benefits, WHO prior agreements for international research, 66, 74, 103–104
post-trial treatment for research participants, justice as reciprocity and, 59–61
protection of participants in international research, ethical requirements, ii–iii, 5–6
protection of participants in international research, mechanisms for, xi–xiv, 13–14, 78–89
randomized withdrawal design, description of, 22
recruitment issues for international research, 10–12
repeating study, design issues, 31–32
resources (funding) support for ethics review of international research, xiii, 85
risk disclosure requirements for, cultural barriers to, 38–39
sample size selection for, 29
Single Project Assurances for protection of research participants in, criticisms of, 79–80
superiority trials, description of, 22
Thailand AIDS vaccines testing, prior agreement on post-trial benefits, 66
therapeutic misconception minimization, for participants in international research, vii–viii, 48
voluntary consent process for international research, vii–viii, 11, 36–38
voluntary consent process, role of others, for international research, vii–viii, 42–45
voluntary informed consent, ethical issues, 35
voluntary participation and undue inducement for, involvement of community leaders, NBAC recommendations, vi, 44
women's informed consent, role of husband in international research, vii, 45
See also Research

Clinton, William J., 72, 73
State of the Union address, 72

Code of Federal Regulations, Title 45, Part 46 (45 CFR 46), 3, 35, 36, 48, 55
assurances for protection of participants in international clinical trials, 78, 79
disclosure requirements for international research participants, vii–viii, 37
equivalent protections for international research participants, provision for, 85, 86, 87, 88, 89
ethics review for protection of international research participants, 81, 82
host country capacity building for international clinical trials, U.S./international guidelines on, 93
protection of international research participants, U.S./ international policy/regulatory issues for, 14
protection of international research participants, U.S. procedures for, 78, 79, 81, 82, 85, 86, 87, 88, 89

Coercion
community leaders role in participation in international clinical trials, NBAC recommendations, vi, 44
inducement (undue) for enrollment in international research, definition and concerns, 46–48

Columbia Laboratories, 108
Columbus, Ohio, 105
Comments. See Public comments

Commission. See National Bioethics Advisory Commission (NBAC)
Commissioned papers. See Papers commissioned
Communities
design/implementation of international clinical trials, involvement in, iv–v, 30–31
education on scientific/technical aspects of research protocols, innovative methods, 41
leaders, involvement in informed consent process for international clinical trials, issues for, 42–44
leaders, involvement in voluntary participation in international clinical trials, NBAC recommendations, vi, 44
post-trial benefits of international research, access to, ethical issues, 55–74
post-trial benefits of international research for host countries, prior agreements on, x, 74
post-trial benefits of international research, obligations of public/private research sponsors, 64–65
post-trial benefits of international research, obligations of researchers, 64
post-trial benefits of international research, obligations to host community, ethical concerns, 61–64
Uganda, leaders involvement in informed consent guidelines for international research, 44

Compensation
participants in international clinical trials, ethical requirements for, 6
participants in international research, documents concerning protection of, comparative analysis of, 100–101
participants in U.S. government-sponsored clinical trials, care/compensation for, NBAC recommendations, iii, 6

Confidentiality See Privacy and confidentiality

Congress, U.S. See U.S. Congress

Consent. See Informed consent

Consent forms. See Documentation; Informed consent

Consent process. See Informed consent

Contraceptive devices
female condom, international research on, UNAIDS prior agreement for post-trial benefits in selected countries, 108

Control groups
dose-comparison concurrent control, 23
established effective treatment in international clinical trials, iv, 9–10, 28
established effective treatment vs. best current methods in developing countries, standard definition, 28
external control, 23
interventions for, cultural barriers to disclosure requirements, 39
nature of, ethical design issues, 23–26
no treatment concurrent control, 23
randomization of, cultural barriers to disclosure requirements, 39
treatment of, ethical design issues, 22, 26–28
Cooperative Project Assurance (CPA), 79, 80

See also Assurances of compliance; International Cooperative Project Assurance; Office for Human Research Protections (OHRP)

Cooperative Protocol Research Program, 79

Cornell University
Medical School, 41

Cote d’Ivoire
UNAIDS prior agreement for post-trial benefits in, 108

Council for International Organizations of Medical Sciences (CIOMS), 3

International Ethical Guidelines for Biomedical Research Involving Human Subjects, 5, 8, 9, 11, 14, 36, 38, 46, 62, 70, 74, 90, 93

International Guidelines for Ethical Review of Epidemiological Studies, 93

international research participants protection, documents concerning, comparative analysis of, 100

“Obligations of Sponsoring and Host Countries,” 62

“Research Involving Subjects in Underdeveloped Communities,” 62

Council of Europe

Convention for the Protection of Human Rights and Dignity of the Human Being with Regard to the Application of Biology and Medicine, 93

international research participants protection, documents concerning, comparative analysis of, 100

CPA. See Cooperative Project Assurance (CPA)

Cultural barriers

alternative therapies, disclosure requirements for international clinical trials and, 39–40

control interventions, disclosure requirements for international clinical trials and, 39

control randomization, disclosure requirements for international clinical trials and, 39

diagnosis/prognoses, disclosure requirements for international clinical trials and, 38–39

disclosure requirements for international clinical trials and, 38–40

informed consent documentation for international clinical trials, issues, 48–50

informed consent process for international clinical trials, variations due to, viii, 50

informed consent process for women in international clinical trials, issues, 45

informed consent process involvement of community leaders for international clinical trials, issues, 43

informed consent process involvement of family members for international clinical trials, issues, 44–45

informed consent process involvement of others for international clinical trials, issues, 42–45

post-trial benefits, disclosure requirements for international clinical trial and, 40

risk information, disclosure requirements for international clinical trials and, 38–39

scientific/technical information explanation for informed consent for international research, innovative methods, 40–42

voluntary consent process, role of others, for international clinical trials, vi–vii, 42–45

D

Data and Safety Monitoring Board (DSMB), 31

Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects, 5, 8, 9, 10, 25, 26, 36, 37, 56, 57, 62, 70, 74, 80, 82, 88, 93, 100
See also World Medical Association (WMA)

Denmark

Act on a Scientific Ethical Committee System and the Handling of Biomedical Research Subjects, 93

international clinical trials, ethics review regulations for, 82

international research participants protection, documents concerning, comparative analysis of, 100

Department of Health and Human Services (DHHS)

international clinical trials, assurance regulations for protection of participants, 79, 80

international clinical trials, ethics review regulations for protection of participants, 81, 82

international research participants, equal protection provision for, xiii, 14, 85–89

Department of the Treasury

Secretary, 72

Design. See Research design

Developing countries. See Research involving developing countries

DHHS. See Department of Health and Human Services (DHHS)

Dickens, Bernard, 88

Disclosure of information

alternative therapies for international research and, cultural barriers to requirements, 39–40

community representatives involvement to ensure comprehension in international clinical trials, vi, 42

control interventions for international research and, cultural barriers to requirements, 39

control randomization for international research and, cultural barriers to requirements, 39

cultural barriers to clinical trial requirements, 38–40

diagnosis/prognoses for international research and, cultural barriers to requirements, 38–39

participants in international clinical trials, informed consent requirements for, v–vi, 37, 40

post-trial benefits from international research, informed consent requirements for, vi, 40

risk to participants of international clinical trials and, cultural barriers to requirements, 38–39

scientific/technical information explanation for international clinical trials, innovative methods, 40–42

See also Information, Informed consent
Index

Diseases and disorders
  diagnosis disclosure requirements for international clinical trials, cultural barriers to, 38–39
disclosure requirements for participants in international clinical trials, v–vi, 37, 40
See also Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS); Respiratory Distress Syndrome (RDS)

Documentation
  Haiti informed consent requirements for international research, 49
  informed consent process for international research, concerns for, 48–50
  informed consent requirements for international research, examples of, 49
  Malawi informed consent requirements for international research, 49
  Nigeria informed consent requirements for international research, 49
  Uganda informed consent requirements for international research, 49

Double standards. See Standards

Drugs and drug testing
  Biologic License Application, 21
development phases, summary of, 21
discovery process for, 21
  investigational device exemption (IDE), 21
  investigational new drug (IND) application, 21
  New Drug Application (NDA), 21
  pivotal trials (confirmatory trials), 21
  post-trial access and prior agreements for international research, funding/distribution issues, 67–69
  preclinical testing, 21
  Product License Application, 21
See also Clinical trials; Placebos; Vaccines and vaccination

DSMB. See Data and Safety Monitoring Board (DSMB)

E
  Effectiveness studies. See Clinical trials
  Efficacy studies. See Clinical trials
  Elizabeth Glaser Pediatric AIDS Foundation
    Call to Action project, 73
  EO 13155. See Executive Order 13155
  Equipoise
    clinical trials and, requirement for, 22–23
definition of, 22
See also Clinical trials; Research design

Equivalent protections. See Protections for human participants

Established effective treatment. See Active treatment concurrent control; Health care

Ethics
  AIDS vaccines development, prior agreements on post-trial benefits, 66
  biomedical researchers in developing countries and U.S., issues for, NBAC survey, 4
  clinical trials in developing countries and, papers commissioned on, 117
  clinical trials in developing countries and, public comments on, 111–113
  clinical trials in developing countries and, testimony, public/expert on, 115
  clinical trials in developing countries, issues for, 3–4
  clinical trials participants, obligations owed to during, 20
control groups treatment in clinical trials in developing countries, concerns, 26–28
design/conduct of international clinical trials, concerns, 19–32
HIV perinatal transmission, placebo-controlled trials in developing countries, controversy, 1, 2
informed consent, standard of, definitions, 36–38
Latin America proposed placebo use in study, concerns, 25
participants in international clinical trials, fair/respectful treatment of, v–vii, 10–12
post-trial benefits for international research, issues, viii–x, 12–13, 55–74
post-trial benefits for others in international research, issues, x, 12–13
post-trial benefits, and researcher-participant relationship in international research, issues, 58–59
post-trial benefits, IAVI prior agreements for international research, 66, 74, 104–106
post-trial benefits, obligations of public/private research sponsors for international research, 64–65
post-trial benefits, obligations of researchers in international research, 64
post-trial benefits, obligations to host community/country of international research, concerns, 61–64
post-trial benefits, obligations to participants in international clinical trials, concerns, 56–58
post-trial benefits, prior agreements for international research, discussion, 66–72, 74
post-trial benefits, prior agreements for international research, and health policy influence, issues, 70–71
post-trial benefits, prior agreements for international research, and prevailing international standard, issues, 70
post-trial benefits, prior agreements for international research, funding/distribution problems for, 67–69
post-trial benefits, UNAIDS prior agreements for international research, 66, 74, 108
post-trial benefits, VaxGen prior agreements for international research, 66, 74, 106–108
post-trial benefits, WHO prior agreements for international research, 66, 74, 103–104
post-trial treatment for participants in international research, justice as reciprocity and, 59–61
  protection of participants in international clinical trials, requirements for, ii–iii, 5–6
protection of participants in international clinical trials, U.S./international policy/regulatory issues, 14
protections for participants in U.S. government-sponsored international clinical trials, NBAC recommendations, ii–iii, 6
recruitment for international clinical trials, issues, 10–12
Thailand AIDS vaccines testing, prior agreement on post-trial benefits, 66
voluntary informed consent, substantive standard of, recommendations, 38
See also Ethics review and review committees

Ethics review and review committees, 6
assurance process for protection of participants in international research, U.S. procedures for, xi, 80
capacity building for developing countries, for international clinical trials, strategies for, NBAC recommendations, xiv, 91
capacity building, for host country in international clinical trials, need to, xiii–xiv, 14, 89–94
capacity building, for host country in international clinical trials, U.S./international guidelines reviewed by NBAC on, 93
clinical trials involving human participants in developing countries, requirements for, xi–xii, 13–14, 81–85
design involvement of community and study participants, for international clinical trials, v, 30–31
design justification to, for protection of participants in international clinical trials, iv, 20
equal protection provision, for participants in international clinical trials, role of, 88, 89
established effective treatment for control groups in developing countries, concerns for, iv, 9–10, 28
financial support for costs of, for research in developing countries, xiii, 85
informed consent for international clinical trials, ensuring comprehension for, vi, 42
informed consent for participants in international clinical trials, disclosure for, NBAC recommendations, vi, 40
informed consent, procedural requirement for international research, cultural barriers to, NBAC recommendations, vii, 50
multiple, for international clinical trials, considerations, 82–84
post-trial benefits for host country population, for international research, NBAC recommendations, x, 74
post-trial benefits, in international research, disclosure in informed consent documents, NBAC recommendations, vi, 40
post-trial treatment/benefits for participants in international research, NBAC recommendations, x, 74
protection of international research participants, challenges to host country review, 82
protection of international research participants, U.S. provisions for, 81, 82, 83, 84, 85
U.S. government-sponsored clinical trials in developing countries, requirements for, NBAC recommendations, xii, 83, 84
voluntary informed consent for participants in international clinical trials, NBAC recommendations, v, 38
women’s informed consent process, role of husband, in international clinical trials, vii, 45
See also Ethics; Institutional Review Boards (IRBs)

Europe
AIDS vaccine research, 91
established effective treatment in international research, example of, 10
Evaluation
international research participants, assurance process for protection of, independent evaluation, NBAC recommendations, xi, 80
See also Ethics review and review committees

Executive Order 13155, 73
Expert testimony See Testimony and speakers

F
Faden, R.R., 36

Families
husbands involvement in informed consent of women, for international clinical trials, cultural issues, 45
informed consent process involvement of, for international clinical trials, vii, 44–45
Uganda informed consent guidelines for involvement, 44
See also Marriage

FDA. See Food and Drug Administration (FDA)

Federal departments and agencies
financial support for ethical review costs of research in developing countries, requirements, xiii, 85
informed consent documentation for international clinical trials, and, recommendations, viii, 50
See also Agency for International Development (USAID); Department of Health and Human Services (DHHS); Department of the Treasury; Federal government; Federal regulation; Food and Drug Administration (FDA)

Federal Food, Drug, and Cosmetic Act, 81

Federal funding for research
ethics review of U.S. government-sponsored international clinical trials, NBAC recommendations, xii, 83, 84
financial support for costs of ethical review of research in developing countries, NBAC recommendations, xii, 85
post-trial obligations of public sponsors, 64–65
protections for participants in U.S. government-sponsored international clinical trials, NBAC recommendations, ii–iii, 6
See also Federal government; Research funding

Federal government
assurances for protection of participants in international clinical trials, explanation, 78–80
ethics review of U.S. government-sponsored clinical trials in developing countries, requirements, NBAC recommendations, xii, 83
protection of participants in international research, documents concerning, comparative analysis of, 101
protection of participants in U.S. government-sponsored international clinical trials, NBAC recommendations, ii–iii, 6
Single Project Assurances for protection of international research participants, criticisms of, 79–80
See also Federal departments and agencies; Federal funding for research; Federal legislation; Federal regulation; Health policy; Public policy; U.S. Congress

Federal legislation
Vaccines for the New Millennium Act of 2000 (S. 2132/H.R. 3812), 72
World Bank AIDS Prevention Trust Fund Act (S. 2033/H.R. 3519), 72
See also Federal Food, Drug, and Cosmetic Act; Federal government; Federal regulation; Public Health Service Act; Public Law 106-264; Public Law 106-429; U.S. Congress

Federal oversight. See Federal regulation

Federal policy. See Federal government; Federal regulation; Health policy; Public policy


Federal regulation
assurances for protection of participants in international clinical trials, explanation, 78–80
equal protection for participants in international research, provision of DHHS, explanation, xiii, 14, 85–89
ethics review for protection of participants in international clinical trials, U.S. procedures, 81–85
host country capacity for international research, variation in U.S./international guidelines for, 92, 93–94
protection of participants in international clinical trials, U.S. procedures for, 78–89
protection of participants in international clinical trials, U.S./international policy/regulatory issues, 14
Single Project Assurances for protection of international research participants, criticisms of, 79–80
See also Federal departments and agencies; Federal government; Public policy

Federalwide Assurance (FWA), 87, 89
Federalwide Domestic Assurance, xi, 80
Federalwide International Assurance, xi, 80
international research participants protection, OHRP proposed revisions to, 80
See also Assurances of compliance

FIC. See Fogarty International Center (FIC)

Finland
international research participants protection, documents concerning, comparative analysis of, 100

Flaherty, M.P., 108

Fogarty International Center (FIC)
International Bioethics Education and Career Development Award Program, 91
See also National Institutes of Health (NIH)

Food and Drug Administration (FDA), 3, 23, 25, 36, 50, 80, 87, 93
drug development phases and, 21
ethics review of international clinical trial, requirements of, xii, 81, 82, 83, 84

protection of participants in international clinical trials, U.S./International policy/regulatory issues, 14
protection of participants in U.S. government-sponsored international clinical trials, requirements of, NBAC recommendations, iii, 6

Foreign countries. See Developing countries; International research

Fost, N.C., 39

France
international research activities of, 3
Law 88-1138 Regarding the Protection of Persons Agreeing to Biomedical Research, 93
protection of international research participants, documents concerning, comparative analysis of, 100

Freedom of choice
inducement (undue) for research enrollment, definition and concerns, 46–48
informed consent process involvement of community leaders, issues, 42–44
informed consent process involvement of family members, issues, 44–45
informed consent process involvement of others, issues, 42–45
voluntary informed consent and, issues, 45–48
women’s voluntary informed consent, issues, 45

FWA. See Federalwide Assurance (FWA)


G

Gambia
clinical trial, community education for informed consent, 41
Gates Foundation. See Bill and Melinda Gates Foundation

Germany
international research activities of, 3
Glantz, L.H., 67
Glaser Foundation. See Elizabeth Glaser Pediatric AIDS Foundation

Glaxo SmithKline Beecham, 73
Glaxo Wellcome, 73

Global AIDS and Tuberculosis Relief Act of 2000. See Public Law 106-264

Global Alliance for Vaccines and Immunization, 72
Global Fund for Children’s Vaccines, 73

Government funding for research. See Federal funding for research

H

Haemophilus influenzae type b, 4, 73

Haiti
established effective treatment, example of, 10
ethics review process in international research, comments on, 84
HIV vaccine trials, scientific information explanation for informed consent, 41
informed consent documentation requirements, 49
Health and Human Services Department. See Department of Health and Human Services (DHHS)

Health care

AIDS vaccines development, prior agreements on post-trial benefits, 66
control groups of U.S. researchers in developing countries, ethical concerns, 26–28
design and routine care, relevance for participants in international clinical trials, iii–iv, 8–10, 20–29
disclosure requirements for control interventions in international clinical trials, cultural barriers, 39–40
established effective treatment for control groups in international clinical trials, iv, 9–10, 28
established effective treatment vs. best current methods, for international clinical trials, 28
HIV perinatal transmission, placebo-controlled trials in developing countries, controversy, 1, 2
host country needs, responsiveness of clinical trials in developing countries to, iii, 7–8
post-trial benefits for host country population, for international research, NBAC recommendations, x, 74
post-trial benefits for international clinical trials, ethical issues, vii–x, 12–13, 55–74
post-trial benefits for participants in international clinical trials, justice as reciprocity and, 59–61
post-trial benefits, IAVI prior agreements for international research, 66, 74, 104–106
post-trial benefits, obligations of public/private research sponsors, 64–65
post-trial benefits, obligations of researchers, 64
post-trial benefits, obligations to host community/country, ethical concerns, 61–64
post-trial benefits, obligations to participants, ethical concerns, 56–58
post-trial benefits, prior agreements for international research, and breach of obligations potential, 72, 74
post-trial benefits, prior agreements for international research, and creation of double standard, issues, 71–72
post-trial benefits, prior agreements for international research, and delay/prevention of research, 68
post-trial benefits, prior agreements for international research, and prevailing international standard, issues, 70
post-trial benefits, prior agreements for international research, discussion, 66–72, 74
post-trial benefits, prior agreements for international research, funding/distribution problems, 67–69
post-trial benefits, prior agreements for international research, health policy influence of, issues, 70–71
post-trial benefits, UNAIDS prior agreements for international research, 66, 74, 108
post-trial benefits, VaxGen prior agreements for international research, 66, 74, 106–108
post-trial benefits, WHO prior agreements for international research, 66, 74, 103–104
post-trial obligations, and researcher-participant relationship, ethical issues for, 58–59
post-trial treatment/benefits for participants in international research, NBAC recommendations, x, 74
protection of participants in international research, documents concerning, comparative analysis of, 100–101
standard of, for participants in international clinical trials, 9, 26–28
Thailand AIDS vaccines testing, prior agreement on post-trial benefits, 66
therapeutic misconception minimization, for participants in international clinical trials, vii–viii, 48
See also Active treatment concurrent control; Health care costs; Health policy, Placebo concurrent control

Health care costs

post-trial benefits for international research, prior agreements for, funding issues for, 68–69
See also Health care

Health policy

prior agreements on post-trial benefits in international research, unrealistic influence on, 70–71
See also Health care; Health care costs; Public policy

Heavily Indebted Poor Countries, 73

Helsinki, Finland. See Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects, Finland

Hippocratic oath, 58

HIV/AIDS. See Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS)

H.M.S. Salisbury, 23

HUGO. See Human Genome Organization (HUGO)

Human Genome Organization (HUGO)

Ethics Committee, 63, 70
Human Genome Project, 63
post-trial benefits access for international research participants, provisions for, 63, 70
Statement on Benefit Sharing, 63, 70

Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS)

maternal-to-infant transmission of, placebo-controlled trials in developing countries, controversy, 1, 2
Thailand vaccines testing, prior agreement on post-trial benefits, 66, 106–108
vaccine development, IAVI prior agreements on post-trial benefits, 66, 74, 104–106
vaccine development, VaxGen prior agreements on post-trial benefits, 66, 74, 106–108
vaccine initiatives timeline 2000–2001, 72–73
vaccine trials, 30, 41

Human participants. See Participants, Protections for human participants

Husbands. See Families; Marriage

Hyder, Adnan, 26, 27, 38, 41, 42, 47, 48, 50, 55, 57, 64, 66, 80, 82, 83, 85, 86, 89–90, 92
I

IAVI. See International AIDS Vaccine Initiative (IAVI)
ICH. See International Conference on Harmonisation (ICH)
IDE. See Investigational device exemption (IDE)
Ijsselmuider, C.B., 36
Illinois, 73
Immtech International, Inc., 73
INCLEN. See International Clinical Epidemiology Network (INCLEN)
IND. See Investigational new drug (IND) application
Independent bodies
international research participants, assurance process for protection of, evaluation by, NBAC recommendations, xi, 80
India
AIDS vaccine development efforts, 106
Ethical Guidelines on Biomedical Research Involving Human Subjects, 87, 93
Indian Council of Medical Research, 87, 93
international clinical trials, ethics review for, 82
international research ethics and voluntary informed consent, 11, 35
international research participants protection, documents concerning, comparative analysis of, 101
Inducement. See Coercion
Infants
Latin America Respiratory Distress Syndrome proposed study, 25
See also Maternity
Influence. See Coercion
Information
scientific/technical, explanation for informed consent, innovative methods, 40–42
See also Disclosure of information; Informed consent
Informed consent
biomedical researchers in developing countries and U.S., ethical issues for, NBAC survey, 4
community leaders involvement in process, cultural issues, 42–44
comprehension of, ensuring, for international clinical trials, vi, 42
cultural issues relating to process of, 40–45
cultural variations to process, for international clinical trials, NBAC recommendations, viii, 50
documentation requirement for, discussion, 37, 38, 48–50
documentation requirement for, examples, 49
documents concerning protection of international research participants, comparative analysis of, 100–101
ethical issues for international research by U.S. researchers, 35–51
ethical standard of, definitions of, 36–38
family members role in process for international clinical trials, vii, 44–45
others involvement in process for international clinical trials, vi, 42–45
post-trial benefits from international research, disclosure for, NBAC recommendations, vi, 40
process of, discussion, 36, 37, 38
recruitment issues for international clinical trials, 10–12
scientific/technical information explanation for, innovative methods, 40–42
substantive standard of, definition, 37–38
therapeutic misconception minimization, for participants in international clinical trials, vii–viii, 48
Uganda involvement of others, new guidelines for, 44
voluntary, for participants in international clinical trials, v–vii, 11, 36–38
voluntary, role of others, for international clinical trials, vi–vii, 42–45
women, role of husband in process for international clinical trials, vii, 45
See also Disclosure of information; Information
Institute of Human Virology, 105
Institutional Review Boards (IRBs), xiv, 6, 13, 19, 20, 24, 39, 41, 50, 65, 66, 92, 94
disclosure requirements for international clinical trials, and, 37
equal protection provision, for research participants in international clinical trials, role of, 87, 88, 89
ethics review for international clinical trials, U.S. procedures concerning, 81, 82, 83, 84, 85
ethics review of U.S. government-sponsored clinical trials in developing countries, requirements, xii, 83, 84
protection of participants in international research participants, U.S. procedures concerning, 78, 79
registration process, for assurances protection of international research participants, and proposed revisions 80, 81
See also Ethics review and review committees
International AIDS Vaccine Initiative (IAVI)
AIDS vaccine development efforts, 72, 73, 104–106
AIDS Vaccines for the World: Preparing Now to Assure Access, 106
international research, prior agreements for post-trial benefits from, 66, 74, 104–106
Scientific Blueprint 2000: Accelerating Global Efforts in AIDS Vaccine Development, 106
Scientific Blueprint for AIDS Vaccine Development, 104–105
Uganda research capacity building, efforts of, 91
International Clinical Epidemiology Network (INCLEN), 91
See also Rockefeller Foundation
International Conference on Harmonisation (ICH), 3, 24
Harmonised Tripartite Guideline, Guideline for Good Clinical Practice (GCP), 36, 37, 38, 87, 88, 93
international research participants protection, documents concerning, comparative analysis of, 100
International Cooperative Project Assurance, 79
See also Assurances of compliance; Cooperative Project Assurance (CPA), Office for Human Research Protections (OHRP)
International Covenant on Civil and Political Rights, 35

International regulation

equal protection for research participants in international research, DHHS provision for, explanation, xiii, 14, 83–89
host country capacity for international research, variation in U.S./international guidelines for building, 92, 93–94
host country review for international research, challenges to, 82
post-trial obligations to international research participants, existing guidelines, 56–58
protection of participants in international clinical trials, comparative analysis of relative documents, 99–101
protection of participants in international clinical trials, U.S./international policy/regulatory issues, 14

International research

AIDS vaccines development, prior agreements on post-trial benefits, 66
alternative therapies disclosure requirements, cultural barriers to, 39–40
assurances of compliance, for protection of participants, xi, 14, 78–80
biomedical researchers in, ethical issues for, NBAC survey, 4
capacity building for host country, variation in U.S. international guidelines for, 92, 93–94
capacity building for, need to, xiii–xiv, 14, 89–94
capacity building for, strategies for, NBAC recommendations, xiv, 91, 94
clinical trials in developing countries, ethical issues for, 3–4
clinical trials in developing countries, reasons for, 6–7
clinical trials in developing countries, recruitment issues, 10–12
control groups treatment in developing countries, ethical concerns for, 26–28
design for protection of participants in, iii–v, 8–10, 20–29
design issues for repeating trials, 31–32
design/implementation, community involvement in, for, iv–v, 30–31
disclosure requirements for, cultural barriers to, 38–40
efficacy (optimal care) vs. effectiveness, distinction, 28–29
equivalent protections for participants in, procedures for, xiii, 14, 83–89
established effective treatment for control groups in, iv, 9–10, 28
ethical concerns for, papers commissioned on, 117
ethical concerns for, public comments on, 111–113
ethical concerns for, testimony, public/expert on, 115
ethical conduct of, requirements for, NBAC recommendations on, 5–6
ethics review by host country for, challenges to, 82
ethics review for protection of participants, requirements, xi–xii, 13–14, 81–85
financial support for costs of ethical review of, requirements, NBAC recommendations, xiii, 85
health needs of host country, responsiveness of clinical trials in developing countries to, iii, 7–8
HIV perinatal transmission, placebo-controlled trials in developing countries, controversy, 1, 2
inducement (undue) for enrollment in, definition/concerns, 46–47
informed consent in, ensuring comprehension, NBAC recommendations, vi, 42
informed consent process, cultural variations for, NBAC recommendations, viii, 50
informed consent role of family members for, vii, 44–45
informed consent role of others for, NBAC recommendations, vi, 43
informed consent, disclosure requirements for participants in, NBAC recommendations, v–vi, 37, 40
multiple ethics review for international research, issues, 82–85
participants fair/respectful treatment in, v–vii, 10–12
participants in, ethical requirements for, 3–6
participants standard of care in, 9, 26–28
post-trial benefits for host country in, NBAC recommendations, x, 74
post-trial benefits for host country, prior agreements for, NBAC recommendations, x, 74
post-trial benefits for others in, ethical issues, x, 12–13
post-trial benefits for participants in, NBAC recommendations, x, 74
post-trial benefits, and researcher-participant relationship, ethical issues, 58–59
post-trial benefits, disclosure in informed consent documents for, NBAC recommendations, vi, 40
post-trial benefits, IAVI prior agreements for, 66, 74, 104–106
post-trial benefits in, ethical issues, vii–x, 12–13, 55–74
post-trial benefits, obligations of public/private research sponsors, 64–65
post-trial benefits, obligations of researchers, 64
post-trial benefits, obligations to host country of, ethical concerns, 61–64
post-trial benefits, obligations to participants in, concerns, 56–58
post-trial benefits, prior agreements on, and breach of obligations potential, 72, 74
post-trial benefits, prior agreements on, and creation of double standard, issues, 71–72
post-trial benefits, prior agreements on, and delay/prevention of research, 68
post-trial benefits, prior agreements on, and funding/distribution problems, 67–69
post-trial benefits, prior agreements on, and health policy influence, issues, 70–71
post-trial benefits, prior agreements on, and prevailing international standard, issues, 70
post-trial benefits, prior agreements on, discussion of, 66–72, 74, 103–108
post-trial benefits, UNAIDS prior agreements for, 66, 74, 108
post-trial benefits, VaxGen prior agreements for, 66, 74, 106–108
post-trial benefits, WHO prior agreements for, 66, 74, 103–104
post-trial treatment for participants, justice as reciprocity and, 59–61
protection of participants in, ethical requirements, ii–iii, 5–6
Index

protection of participants in, mechanisms for, xi–xiv, 13–14, 78–89
resources (funding) support for ethics review of, xiii, 85
risk disclosure requirements for, cultural barriers to, 38–39
Single Project Assurances for protection of participants in, criticisms of, 79–80
standard of care for participants in, 9, 26–28
Thailand AIDS vaccines testing, prior agreement on post-trial benefits, 66
therapeutic misconception minimization, for participants in, vii–viii, 48
voluntary consent process for, role of others, vii, 42–45
voluntary consent process for, v–vii, 11, 36–38
voluntary informed consent for, ethical issues, 35
voluntary participation and undue inducement for, involvement of community leaders, NBAC recommendations, vi, 44
women's informed consent for, role of husband in, vii, 45
See also Research
Interventions. See Health care
Investigational device exemption (IDE), 82, 83
Investigational new drug (IND) application, 82, 83
IRBs. See Institutional Review Boards (IRBs)

J
Japan
international research activities of, 3
Johns Hopkins University, 4
School of Hygiene and Public Health, 40–41
Joint United Nations Programme on HIV/AIDS (UNAIDS), 73, 107
Community Involvement and Impact, 30
Ethical Considerations in HIV Preventive Vaccine Research, 8, 14, 57, 93
Ethical Review Committee, 30
Guidance Document for Preventive HIV/AIDS Vaccine Trials, 62, 68, 70, 74, 90, 92
HIV vaccine research in developing countries, capacity building mechanisms for, listing, 90
post-trial benefits for international research, prior agreements for, 66, 74, 108
protection of international research participants, documents concerning, comparative analysis of, 100
See also United Nations (UN)
Justice
distributive, ethical obligation for international clinical trials, summary, 77
fairness principle, and post-trial obligations to host community/country, ethical concerns, 61–64
reciprocity principle in clinical trials, and participants post-trial access to benefits, 59–61
K
Kass, Nancy, 26, 27, 38, 41, 42, 47, 48, 50, 55, 57, 64, 66, 80, 82, 83, 85, 86, 89–90, 92
Kenya
Nairobi, AIDS vaccine development efforts, 105
Trypanosomiasis Research Institute, 73
See also University of Nairobi
Kerry, John, 72

L
Languages
Creole, informed consent for international research, form in, 41
English, informed consent for international research, form in, 41
French, informed consent for international research, form in, 41
translation of scientific/technical aspects of research protocols for informed consent, innovative methods, 41
Latin America
informed consent documentation requirements, issues, 49–50
placebo vs. established effective treatment in proposed study, ethical concerns, 25
Leach, Jim, 72
Lesotho
UNAIDS prior agreement for post-trial benefits in, 108
Lind, James, 23
London School of Hygiene and Tropical Medicine, 73
See also United Kingdom
Loue, Sana, 44, 92
Love, R.R., 39

M
Mali
informed consent process involvement of community leaders, issues for, 43
Malawi
informed consent documentation requirements, 49
informed consent process involvement of community leaders, issues for, 43
malaria drugs clinical trials, 43, 49, 62
Ministry of Health, 62
Malenga, Grace, 49, 62
Maternity
HIV perinatal transmission, placebo-controlled trials in developing countries, controversy, 1, 2
See also Infants; Women
Marriage
husbands involvement in informed consent of women, for international clinical trials, vii, 45
See also Families
Marshall, Patricia, 40, 41, 44, 49, 84, 85
Maryland. See University of Maryland
Medicaid, 71
Medical costs. See Health care costs
Medical interventions/treatment. See Health care
Medicare, 55
Merck, 72, 73
Millennium Vaccine Initiative, 72
MPAs. See Multiple Project Assurances (MPAs)
Multiple Project Assurances (MPAs), 79, 80, 89
See also Assurances of compliance; Office for Human Research Protections (OHRP)

N
National Bioethics Advisory Commission (NBAC), i, 3, 9, 10, 11, 13, 14, 15, 19, 24, 26, 32, 36, 37, 39, 41, 46, 47, 49, 51, 55, 56, 57, 60, 61, 62, 63, 64, 65, 67, 68, 70, 71, 77, 78, 81, 82, 86, 87, 88, 92
assurance process for protecting international research participants, recommendations, vi, 80
biomedical researchers in developing countries and U.S., ethical issues for, survey, 4
capacity building for design/review/conduct of clinical trials by developing countries, strategies for, recommendations, xiv, 91
capacity building for international research, for ethics review committees in developing countries, assistance for, recommendations, xiv, 94
design/conduct of international clinical trials, ethical concerns, recommendations, iv, 20, 28, 30–31
design/implementation of international clinical trials, involvement of community, recommendations, v, 30–31
equivalent protections for participants in international research, determination of, recommendations, xii, 89
established effective treatment for control groups in international clinical trials, recommendations, iv, 28
ethics review of U.S. government-sponsored clinical trials in developing countries, requirements, recommendations, xii, 83
financial support for costs of ethical review of research in developing countries, requirements, recommendations, xiii, 85
health needs of host country, responsiveness of clinical trials in developing countries, iii, 8
host country capacity building, for international research, review of U.S./international guidelines on, 93
inducement (undue) and voluntary participation in international clinical trials, involvement of community leaders, vi, 44
informed consent for participants in U.S. government-sponsored international clinical trials, recommendations, iii, 6
informed consent process for international clinical trials, cultural variations for, recommendations, vii, 50
informed consent process for international clinical trials, disclosure requirements, recommendations, vi, 40
informed consent process for international clinical trials, ensuring comprehension for, recommendations, vi, 42
informed consent process for international clinical trials, involvement of family members, recommendations, vii, 43
informed consent process for international clinical trials, involvement of community leaders, recommendations, vi, 42, 43, 44
informed consent process for international clinical trials, involvement of others, recommendations, vi, 43, 44, 45
post-trial benefits for host country from international research, recommendations, x, 74
post-trial benefits for host country from international research, prior agreements on, recommendations, x, 74
post-trial benefits from international research, disclosure in informed consent documents, recommendations, vi, 40
post-trial benefits/treatment for participants in international research, recommendations, x, 74
protections for participants in U.S. government-sponsored international clinical trials, recommendations, iii, vii, 6
risk minimization, for participants in U.S. government-sponsored international clinical trials, recommendations, iii, vii, 6, 84
scientific/technical aspects of research protocols, explanation for informed consent, innovative methods, recommendations, 42
therapeutic misconception minimization, for participants in international clinical trials, recommendations, viii, 48
voluntary informed consent for participants in international clinical trials, recommendations, v, 38
women's informed consent process for international clinical trials, role of husband, recommendations, vii, 45
National Commission. See National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 63, 80
Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, ii, 5, 10, 27, 62–63, 80
National Consensus Conference on Bioethics and Health Research in Uganda, 44
National Institutes of Health (NIH), viii, 2, 7, 50, 85, 91
See also Fogarty International Center (FIC)
NBAC. See National Bioethics Advisory Commission (NBAC)
Netherlands
AIDS vaccine development funding for IAVI, 106
informed consent documentation requirements, issues, 49–50
international research activities of, 3
protection of international research participants, documents concerning, comparative analysis of, 101
Law Regarding Medical-Scientific Research on Humans, 93
New Zealand
HRC Guidelines on Ethics in Health Research, 93
international clinical trials, ethics review for, 82
international research participants protection, documents concerning, comparative analysis of, 101
NGOs. See Nongovernmental organizations (NGOs)
Nigeria
informed consent documentation requirements, 49
informed consent involvement of women's husbands, issues for, 44
Index

Lagos, ethics review committees, comments on, 84
research disclosure requirements, cultural barriers to, 39
scientific/technical information explanation for informed
consent, translation for, 41
NIH. See National Institutes of Health (NIH)
Nongovernmental organizations (NGOs), 7, 69, 72
North Carolina, 105
See also Chapel Hill, North Carolina; University of North
Carolina
Nuffield Council on Bioethics, 90
Nuremberg Code, v, 11, 93
international research participants protection, documents
concerning, comparative analysis of, 100
O
Obligations
AIDS vaccines development, prior agreements on post-trial
benefits, 66
clinical trial participants and, ethical considerations, 20
post-trial benefits for host community/country of international
research, ethical concerns, 61–64
post-trial benefits for international research participants, ethical
concerns, 55–74
post-trial benefits in international research, and researcher-
participant relationship, ethical concerns, 58–59
post-trial benefits in international research, prior agreements
for, and delay/prevention of research, 68
post-trial benefits in international research, prior agreements
for, and prevailing international standard, 70
post-trial benefits in international research, prior agreements
for, discussion of, 66–72, 74, 104–106
post-trial benefits in international research, prior agreements
for, double standard creation, 71–72
post-trial benefits in international research, prior agreements
for, potential breach of, 72, 74
post-trial benefits in international research, prior agreements
for, health policy influence of, issues, 70–71
post-trial benefits in international research, prior agreements
for, funding/distribution problems for, 67–69
post-trial benefits in international research, public/private
research sponsors and, 64–65
post-trial benefits in international research, researchers and, 64
post-treatment for international research participants,
justice as reciprocity and, 59–61
protection of participants in international research, comparison
of documents concerning, 100–101
Thailand AIDS vaccines testing, prior agreement on post-trial
benefits, 66
Office for Human Research Protections (OHRP), 81
assurance system for protection of international research
participants, current practices of, 79, 80
assurance system for protection of international research
participants, proposed revisions of, 80
equal protection provision, for international research
participants, implementation by, xiii, 14, 85, 87–89
See also Cooperative Project Assurance (CPA); International
Cooperative Project Assurance; Multiple Project Assurances
(MPAs); Office for Protection from Research Risks (OPRR);
Single Project Assurances (SPAs)
Office for Protection from Research Risks (OPRR), xiii, 14, 79, 84,
87, 88
See also National Institutes of Health (NIH); Office for Human
Research Protections (OHRP)
Ohio. See Columbus, Ohio
OHRP. See Office for Human Research Protections (OHRP)
Okello, D., 44
OPRR. See Office for Protection from Research Risks (OPRR)
Oversight. See Federal regulation; International regulation
Oxford University. See University of Oxford

P
Pape, Jean, 41, 42, 49, 84
Papers commissioned
international clinical trials, protection of participants, ethical
concerns, 117
Participants. See Protections for human participants
Pelosi, Nancy, 72
PL. 106-264. See Public Law 106-264
PL. 106-429. See Public Law 106-429
Placebo concurrent control
active treatment concurrent control vs., ethical concerns, 25
explanation of, 23–26
Latin America proposed study use, ethical concerns, 25
See also Clinical trials; Control groups; Placebos
Placebos
effect, explanation of, 23–24
HIV perinatal transmission, controversial trials in developing
countries, 1, 2
See also Drugs and drug testing; Placebo concurrent control
Plowe, Christopher, 62
Policy. See Health policy; Public policy
Positive control. See Active treatment concurrent control
Presidential Advisory Council on HIV/AIDS, 73
Prevailing standards. See Standards
Prior agreements
AIDS vaccines development, post-trial benefits and, 66
IAVI, for post-trial benefits in international research,
description, 66, 74, 104–106
post-trial benefits access to others in international research,
ethical issues, x, 12
post-trial benefits for host country population in international
research, and, NBAC recommendations, x, 74
post-trial benefits in international research and, discussion,
66–72, 74, 104–108
post-trial benefits in international research and, double standard creation, issues, 71–72
post-trial benefits in international research and, funding/distribution problems, 67–69
post-trial benefits in international research and, health policy influence, issues, 70–71
post-trial benefits in international research and, potential breach of obligations, 72, 74
post-trial benefits in international research and, prevailing international standard and, issues, 70
post-trial benefits in international research and, research delay/prevention and, 68
Thailand AIDS vaccines testing, and post-trial benefits, 66, 106–108
UNAIDS, for post-trial benefits in international research, description, 66, 74, 108
VaxGen, for post-trial benefits in international research, description, 66, 74, 106–108
WHO, for post-trial benefits in international research, description, 66, 74, 103–104
Privacy and confidentiality
protection of participants in international research, comparison of documents concerning, 100–101
Private sector
post-trial obligations of international research sponsors from, 64–65
Protections for human participants
AIDS vaccines development, prior agreements on post-trial benefits, 66
assurances of compliance, for international clinical trials, xi, 14, 78–80
biomedical researchers in, ethical issues for, NBAC survey, 4
clinical trials in developing countries and, mechanisms for, xi–xiv, 13–14, 78–89
clinical trials in developing countries and, U.S./international policy/regulatory issues, 14
clinical trials in developing countries sponsored by U.S. government and, NBAC recommendations, ii–iii, 6
clinical trials in developing countries, ethical requirements for, ii–iii, 5–6
clinical trials in developing countries, recruitment issues, 10–12
control groups treatment in developing countries, ethical concerns for, 26–28
design and routine care for, in international clinical trials, iii–iv, 8–9, 20–29
design involvement of, for international clinical trials, 30–31
equivalent protections for, procedures for, xiii, 14, 85–89
ethical concerns for, papers commissioned on, 117
ethical concerns for, public comments on, 111–113
ethical concerns for, testimony, public/expert on, 115
ethics review by host country for, challenges to, 82
ethics review for protection of participants, requirements, xi–xii, 13–14, 81–85
existential loss of, in international research, 58–59
fair/respectful treatment of, in international clinical trials, v–vii, 10–12
HIV perinatal transmission, placebo-controlled trials in developing countries, controversy, 1, 2
inducement (undue) for enrollment in, definition/concerns, 46–47
informed consent process for international research, cultural variations for, NBAC recommendations, viii, 50
informed consent process for international research, ensuring comprehension, NBAC recommendations, vi, 42
informed consent process for international research, role of family members for, vii, 44–45
informed consent process for international research, role of others for, NBAC recommendations, vi, 43
informed consent, disclosure requirements for international research, cultural barriers to, 38–40
informed consent, disclosure requirements for international research, NBAC recommendations, v–vi, 37, 40
international documents concerning, comparative analysis of, 99–101
multiple ethics review for international clinical trials, issues for, 82–85
post-trial benefits for host country in, NBAC recommendations, x, 74
post-trial benefits for host country population, for international research, NBAC recommendations, x, 74
post-trial benefits, IAVI prior agreements for, 66, 74, 104–106
post-trial benefits, in international research, ethical issues, viii–x, 12–13, 55–74
post-trial benefits, obligations of public/private research sponsors, 64–65
post-trial benefits, obligations of researchers, 64
post-trial benefits, prior agreements for international research, and breach of obligations potential, 72, 74
post-trial benefits, prior agreements for international research, and creation of double standard, issues, 71–72
post-trial benefits, prior agreements for international research, and delay/prevention of research, 68
post-trial benefits, prior agreements for international research, and funding/distribution problems, 67–69
post-trial benefits, prior agreements for international research, and health policy influence, issues, 70–71
post-trial benefits, prior agreements for international research, and prevailing international standard, issues, 70
post-trial benefits, prior agreements for international research, discussion of, 66–72, 74, 103–108
post-trial benefits, UNAIDS prior agreements for, 66, 74, 108
post-trial benefits, VaxGen prior agreements for, 66, 74, 106–108
post-trial benefits, WHO prior agreements for, 66, 74, 103–104
post-trial obligations to, ethical concerns, 56–58
post-trial obligations to, relationship with researcher and, ethical issues, 58–59
post-trial treatment for participants, justice as reciprocity and, 59–61
post-trial treatment/benefits for participants in international research, NBAC recommendations, x, 74
Single Project Assurances for, criticisms of for research in developing countries, 79–80
standard of care for, in international clinical trials, 9, 26–28
Thailand AIDS vaccines testing, prior agreement on post-trial benefits, 66
therapeutic misconception minimization, for international clinical trials, vii–viii, 48
voluntary consent, concerns for, 45–48
voluntary informed consent for international clinical trials, v–vii, 11, 36–38
voluntary participation and undue inducement for, involvement of community leaders, NBAC recommendations, vi, 44
women’s informed consent for international clinical trials, role of husband in, vii, 45
See also Research

Public comments
international clinical trials, protection of participants, ethical issues, 111–113
See also Testimony and speakers

Public Health Service Act, 81, 91
Public Law 106-264, 73
Public Law 106-429, 73, 106
Public policy
protection of participants in international clinical trials, U.S./international policy/regulatory issues, 14
See also Federal government, Federal regulation, Health policy

Public testimony. See Testimony and speakers

R
Randomization
clinical trials, and, 22, 23
clinical trials, and disclosure requirements, cultural barriers to, 39
See also Clinical trials; Research design

RDS. See Respiratory Distress Syndrome (RDS)

Reciprocity
justice as, and participants access to post-trial treatment in international research, 59–61

Recommendations
assurance process for protecting international research participants, xi, 80
capacity for international research, for ethics review committees in developing countries, assistance for building, xiv, 94
capacity of developing countries to design/review/conduct clinical trials, strategies for building, xiv, 91
design/conduct of international clinical trials, ethical concerns, iv, 20, 28, 30–31
design/implementation of international clinical trials, involvement of community, v, 30–31
disclosure for informed consent of participants in international clinical trials, vi, 40
equivalent protections for participants in international research, determination of, xiii, 89
established effective treatment for control groups in international clinical trials, iv, 28

ethics review of U.S. government-sponsored clinical trials in developing countries, requirements, xii, 83
financial support for costs of ethical review of research in developing countries, requirements, xiii, 85
health needs of host country, responsiveness of clinical trials in developing countries, iii, 8
inducement (undue) and voluntary participation in international clinical trials, involvement of community leaders, vi, 44
informed consent for participants in U.S. government-sponsored international clinical trials, iii, 6
informed consent in international clinical trials, ensuring comprehension for, vi, 42
informed consent process for international clinical trials, involvement of family members, vii, 45
informed consent process for international clinical trials, involvement of community leaders, vi, 42, 43, 44
informed consent process for international clinical trials, involvement of others, vi, 43, 44, 45
informed consent process, cultural variations for international clinical trials, viii, 50
post-trial benefits for host country from international research, x, 74
post-trial benefits for host country from international research, prior agreements on, x, 74
post-trial benefits from international research, disclosure in informed consent documents, vi, 40
post-trial benefits/treatment for participants in international research, x, 74
protections for participants in U.S. government-sponsored international clinical trials, ii–iii, 6
risk minimization, for participants in U.S. government-sponsored international clinical trials, iii, xii, 6, 84
scientific/technical aspects of research protocols, explanation for informed consent, innovative methods, 42
therapeutic misconception minimization, for participants in international clinical trials, vii, 48
voluntary informed consent for participants in international clinical trials, v, 38
women’s informed consent process for international clinical trials, role of others, 45
women’s informed consent process for international clinical trials, role of husband, vii, 45

Regulation. See Federal government; Federal regulation; International regulation

Relationships. See Families; Marriage

Relatives. See Families; Marriage

Research
inducement (undue) for participation in, definition and concerns, 46–48
informed consent disclosure requirements, description, 37
therapeutic misconception of, minimization of, 48
voluntary participation in, concerns for, 45–48
See also Clinical trials; International research; Protections for human participants; Research design; Research funding; Research involving developing countries; Research regulation; Science and technology
Research design
- capacity of developing countries to design/review/conduct clinical trials, strategies for building, NBAC recommendations, xiv, 91
- community involvement in, for international clinical trials, iv–v, 30–31
- community/participants involvement in, for international clinical trials, v, 30–31
- ethical concerns for international clinical trials, 19–32
- host country health needs, responsiveness of clinical trials in developing countries, NBAC recommendations, iii, 8
- information disclosure for informed consent of participants in international clinical trials, NBAC recommendations, vi, 40
- medical treatment for participants in clinical trials in developing countries, ethical concerns, 26–28
- participants protection in international clinical trials, NBAC recommendations, iv, 20
- participants routine care in international clinical trials, and, iii–iv, 8–9, 20–29
- repeating study in developing country, issues for international research, 31–32
- results (interim), monitoring issues for international research, 31
- sample size determination for international critical trials, 29
See also Equipoise; Randomization; Research

Research funding
- capacity of developing countries to design/review/conduct clinical trials, strategies for building, NBAC recommendations, xiv, 91
- post-trial obligations of public/private sponsors of international clinical trials, 64–65
- resources support for ethics review of international clinical trials, xiii, 85
See also Federal funding for research; Research

Research involving developing countries
AIDS vaccines development, prior agreements on post-trial benefits, 66
- assurances of compliance, for protection of international research participants, xi, 14, 78–80
- biomedical researchers in, ethical issues for, NBAC survey, 4
- capacity building for host country, for international clinical trials, variation in U.S./international guidelines for, 92, 93–94
- capacity building for international clinical trials, need to, xiii–xiv, 14, 89–94
- capacity building for international clinical trials, strategies for, NBAC recommendations, xiv, 91, 94
- clinical trials conducted in, reasons for, 6–7
- control groups treatment in international clinical trials, ethical concerns for, 26–28
- design for protection of participants in international clinical trials, iii–iv, 8–9, 20–29
- design issues for repeating clinical trials, 31–32
- design/implementation, community involvement in, for international clinical trials, iv–v, 30–31
- efficacy (optimal care) vs. effectiveness trials, distinction, 28–29
- equivalent protections for research participants in, procedures for, xiii, 14, 83–89
- established effective treatment for control groups in international clinical trials, iv, 9–10, 28
- ethical concerns for, papers commissioned on, 117
- ethical concerns for, public comments on, 111–113
- ethical concerns for, testimony, public/expert on, 115
- ethical issues for clinical trials conducted in, 3–4
- ethics review by host country for international research, challenges to, 82
- ethics review for protection of participants in international clinical trials, requirements, xi–xii, 13–14, 81–85
- financial support for costs of ethical review of, requirements, NBAC recommendations, xiii, 89
- health needs of host country, responsiveness of international clinical trials, iii, 7–8
- HIV perinatal transmission, placebo-controlled trials in, controversy, 1, 2
- informed consent in international clinical trials, ensuring comprehension, NBAC recommendations, vi, 42
- informed consent process, cultural variations for international clinical trials, NBAC recommendations, vii, 50
- informed consent role of family members for international clinical trials, vii, 44–45
- informed consent role of others for international clinical trials, NBAC recommendations, vii, 43
- informed consent, disclosure requirements for participants in international clinical trials, NBAC recommendations, v–vi, 37, 40
- multiple ethics review for international clinical trials, issues, 82–85
- participants fair/respectful treatment in international clinical trials, v–vi, 10–12
- participants in international clinical trials, ethical requirements for, 5–6
- participants standard of care in international clinical trials, 9, 26–28
- post-trial benefits for host country in international research, NBAC recommendations, x, 74
- post-trial benefits for host country, prior agreements for international research, NBAC recommendations, x, 74
- post-trial benefits for others in international research, ethical issues, x, 12–13
- post-trial benefits for participants in international research, NBAC recommendations, x, 74
- post-trial benefits, and researcher-participant relationship, ethical issues, 58–59
- post-trial benefits, disclosure in informed consent documents for, NBAC recommendations, vi, 40
- post-trial benefits, IAVI prior agreements for international clinical trials, 66, 74, 104–106
- post-trial benefits, in international research, ethical issues, vii–x, 12–13, 55–74
- post-trial benefits, obligations of public/private research sponsors, 64–65
- post-trial benefits, obligations of researchers, 64
- post-trial benefits, obligations to host country of international clinical trials, ethical concerns, 61–64
- post-trial benefits, obligations to participants in international clinical trials, concerns, 56–58
post-trial benefits, prior agreements for, summary of, 103–108
post-trial benefits, prior agreements on international research, discussion, 66–72, 74
post-trial benefits, prior agreements on, and breach of obligations potential, 72, 74
post-trial benefits, prior agreements on, and creation of double standard, issues, 71–72
post-trial benefits, prior agreements on, and delay/prevention of research, 68
post-trial benefits, prior agreements on, and funding/distribution problems, 67–69
post-trial benefits, prior agreements on, and health policy influence, issues, 70–71
post-trial benefits, prior agreements on, and prevailing international standard, issues, 70
post-trial benefits, UNAIDS prior agreements for international clinical trials, 66, 74, 108
post-trial benefits, VaxGen prior agreements for international clinical trials, 66, 74, 106–108
post-trial benefits, WHO prior agreements for international clinical trials, 66, 74, 103–104
post-trial treatment for research participants, justice as reciprocity and, 59–61
protection of participants in international clinical trials, ethical requirements, ii–iii, 5–6
protection of participants in international clinical trials, mechanisms for, xi–xiv, 13–14, 78–89
recruitment issues for international clinical trials, 10–12
resources (funding) support for ethics review of international clinical trials, xiii, 83
Single Project Assurances (SPAs) for protection of research participants in, criticisms of, 79–80
Thailand AIDS vaccines testing, prior agreement on post-trial benefits, 66
therapeutic misconception minimization, for participants in international clinical trials, vii–viii, 48
voluntary consent process for international clinical trials, v–vii, 11, 36–38
voluntary consent process, role of others, for international clinical trials, vii–vii, 42–45
voluntary informed consent, ethical issues, 35
voluntary participation and undue inducement for, involvement of community leaders, NBAC recommendations, vi, 44
women's informed consent, role of husband in international clinical trials, vii, 45
See also Research
Research regulations
equal protection for participants in international research, provision of DHHS, explanation, xiii, 14, 85–89
ethics review for protection of participants in international clinical trials, U.S. procedures, 81–85
host country capacity for international research, variation in U.S./international guidelines for, 92, 93–94
protection of participants in international clinical trials, challenges to host country review, 82
protection of participants in international clinical trials, U.S./international policy/regulatory issues, 14
protection of participants in international clinical trials, U.S. procedures for, 78–89
See also Research
Respiratory Distress Syndrome (RDS)
Latin America infants proposed study using placebo vs. established effective treatment, 25
See also Diseases and disorders
Review bodies. See Ethics review and review committees; Institutional Review Boards (IRBs)
Risk
disclosure requirements for clinical trials, cultural barriers to, 38–39
disclosure requirements for participants informed consent, in international clinical trials, v–vi, 37, 40
minimization of, for participants in U.S. government-sponsored clinical trials, NBAC recommendations, iii, 6
Roche, 73
Rockefeller Foundation, 91
See also International Clinical Epidemiology Network (INCLEN)
S
Safeguards. See Protections for human participants
Salmonella bacteria, 105
Scandinavia
international research activities of, 3
Science and technology
information, explanation for informed consent in international clinical trials, innovative methods, 40–42
Seattle, Washington, 105
Senegal
literacy rates, summary, 41
scientific/technical information explanation for research study, 41
Single Project Assurances (SPAs), 79, 80
criticisms of, for research in developing countries, 79–80
See also Assurances of compliance; Office for Human Research Protections (OHRP)
Sommer, Alfred, 40–41
South Africa
AIDS vaccine development efforts, 105, 106
Guidelines on Ethics for Medical Research, 90, 93
Medical Research Council, 105
National Institute of Virology, 105
post-trial benefits access for international research participants, guidelines for, 57
protection of participants in international research, comparative analysis of documents concerning, 101
UNAIDS prior agreement for post-trial benefits in, 108
See also University of Capetown
SPAs. See Single Project Assurances (SPAs)
Standards
- double, prior agreements for post-trial benefits in international research, and creation of, issues, 71–72
- health care, for participants in international clinical trials, explanation of, 9
- prevailing, prior agreements for post-trial benefits in international research, problems, 70–71
- protection of participants in international research, documents concerning, comparative analysis of, 100–101

Statistics. See Randomization

Struck, D., 108

Substantive standard of informed consent. See Informed consent

Sugarman, Jeremy, 38, 49

Surveys and questionnaires
- biomedical researchers in developing countries and U.S., ethical issues for, 4, 20, 26, 27, 53, 56, 64, 80, 82, 83, 85, 86, 89–90, 92

Switzerland
- informed consent documentation requirements for international research, issues, 49–50

T

Tanzania
- National Institute for Medical Research, 73

Targeted Genetics Corporation (TGC), 105

Technology. See Science and technology

Testimony and speakers
- international clinical trials, protection of participants in, ethical concerns, 115
  See also Public comments

TGC. See Targeted Genetics Corporation (TGC)

Thailand
- AIDS Call to Action project in, 73
- AIDS vaccine research, prior agreements on post-trial benefits, 66, 106–108
- Bangkok, 107, 108
- Bangkok Metropolitan Association, 107
- female condom research, UNAIDS prior agreement for post-trial benefits, 108
- HIV perinatal transmission, placebo-controlled trials in, controversy, 1, 2
- Mahidol University, 107
- Ministry of Public Health, 107
- protection of participants in international research, documents concerning, comparative analysis of, 101
- Rule of the Medical Council on the Observance of Medical Ethics, 93
- Senate, 108
- voluntary informed consent and international research ethics, 11, 35

Therapeutic misconception
- minimization of, for participants in international clinical trials, vii–viii, 48

Translation. See Languages

Treatment. See Active treatment concurrent control; Health care

Trials. See Clinical trials

U

Uganda
- AIDS vaccine development efforts, 105
- capacity building efforts for international research in, 91, 93
- Guidelines for the Conduct of Health Research Involving Human Subjects in Uganda, 44, 49, 57, 62, 93
- informed consent documentation requirements, 49
- informed consent process involvement of others, new guidelines for, 44
- Ministry of Health, 91
- Ministry of Justice, 93
- National Council of Science and Technology, 93
- National Drug Authority, 93
- post-trial obligations to international research participants, guidelines for, 57, 70
- protection of international research participants, documents concerning, comparative analysis of, 101
- voluntary informed consent and ethics in international research, 11, 35

UN. See United Nations (UN)

UNAIDS. See Joint United Nations Programme on HIV/AIDS (UNAIDS)

Undue influence. See Coercion

United Kingdom
- AIDS vaccine development funding for IAVI, 106
- Guidelines for Good Clinical Practice in Clinical Trials, 93
- Interim Guidelines for Research Involving Human Participants in Developing Societies: Ethical Guidelines for MRC-Sponsored Studies, 57, 93
- international clinical trials, ethics review for, 82
- international research activities of, 3
- Medical Research Council (MRC), 48, 57
- post-trial obligations to international research participants, guidelines for, 57, 70
- protection of international research participants, documents concerning, comparative analysis of, 101
  See also London School of Hygiene and Tropical Medicine; University of Oxford

United Nations (UN), 103, 104
  See also Joint United Nations Programme on HIV/AIDS (UNAIDS); United Nations Children’s Fund; United Nations Population Fund

United Nations Children’s Fund, 73
  See also United Nations (UN)

United Nations Population Fund, 73
  See also United Nations (UN)

United Nations Programme on HIV/AIDS. See Joint United Nations Programme on HIV/AIDS (UNAIDS)
Index

Universal Declaration of Human Rights, 10

Universities
  See also Cornell University; Johns Hopkins University; London School of Hygiene and Tropical Medicine; University of Capetown; University of Maryland; University of Nairobi; University of North Carolina; University of Oxford; Vanderbilt University

University of Capetown, 105
  See also South Africa

University of Maryland
  Biotechnology Institute, 91

University of Nairobi, 105
  See also Kenya

University of North Carolina, 73
  See also North Carolina

University of Oxford, 105
  See also United Kingdom

USAID. See Agency for International Development (USAID)

U.S. Congress, 72
  House of Representatives, 73
  Senate, 73

U.S. government. See Federal government; Federal regulation; Public policy; U.S. Congress

U.S. Public Health Service Act. See Public Health Service Act

V

Vaccines and vaccination
  AIDS/HIV, development, and prior agreements on post-trial benefits, 66, 74
  AIDS/HIV, development, IAVI prior agreements on post-trial benefits, 66, 74, 104–106
  AIDS/HIV, development, VaxGen prior agreements on post-trial benefits, 66, 74, 106–108
  AIDS/HIV, trials for, 30, 41
  Haemophilus influenzae type b, trial for, 41
  initiatives timeline 2000–2001, 72–73
  Thailand AIDS/HIV vaccine research, prior agreements on post-trial benefits, 66, 106–108
  See also Drugs and drug testing

Vanderbilt University, 41

VaxGen
  international research, and prior agreements for post-trial benefits, 66, 74, 106–108
  Thailand AIDS/HIV vaccine research, prior agreements on post-trial benefits, 66, 74, 106–108

Vietnam
  alternative therapies disclosure requirements for clinical trials, cultural barriers to, 39–40

Voluntary consent. See Coercion; Informed consent

W


Washington, D.C., 84

Washington Post, 107

Wellcome Trust Research Laboratories, 73

White House, 72

WHO. See World Health Organization (WHO)

WMA. See World Medical Association (WMA)

Women
  condom (female), international research on, prior agreement for, 108
  informed consent for international clinical trials, role of husband, vii, 45
  informed consent for international clinical trials, role of others in, cultural issues, 45
  See also Maternity

World Bank, 72, 105
  World Bank AIDS Trust Fund, 73

World Health Organization (WHO), 3, 73, 85, 107
  Compound for Distribution in both Public and Private Sectors, 104
  Guidelines on Interaction with Commercial Enterprises, 103
  Memorandum of Understanding (MOU), 103–104
  Operational Guidelines for Ethics Committees That Review Biomedical Research, 62, 70, 92
  Policy on Patents: Information Paper on WHO Patents Policy, 103
  post-trial benefits for international research, prior agreements for, 66, 74, 103–104

World Medical Assembly Declaration, 86

World Medical Association (WMA), 3, 8, 36, 56, 80
  See also Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects

Z

Zambia
  international research, UNAIDS prior agreement for post-trial benefits in, 108

Zimbabwe
  international research, UNAIDS prior agreement for post-trial benefits in, 108